Synairgen plc (LON:SNG)‘s stock had its “corporate” rating reissued by FinnCap in a research report issued on Wednesday.

Synairgen plc (LON:SNG) remained flat at GBX 10.75 during trading on Wednesday. The stock had a trading volume of 30,994 shares. The firm’s market cap is GBX 9.84 million. The firm has a 50 day moving average of GBX 20.26 and a 200 day moving average of GBX 19.75. Synairgen plc has a 1-year low of GBX 7.00 and a 1-year high of GBX 37.90.

ILLEGAL ACTIVITY NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at

Synairgen plc Company Profile

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease.

Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with's FREE daily email newsletter.